Association of serum albumin level with bleeding event in patients with venous thromboembolism treated with oral anticoagulants

The authors aimed to investigate the relationship between serum albumin levels and bleeding events in patients with venous thromboembolism receiving oral anticoagulants. Their analysis of 732 patients revealed that lower serum albumin levels were significantly associated with an increased risk of bleeding events within 180 days, particularly in patients with active cancer. This suggests that serum albumin may serve as a useful biomarker for assessing bleeding risk in this patient population.